Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD
Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary Parkinson's Dissease
This is a non-randomized, open label, dose-escalation study to evaluate the safety and efficacy of KL002 in the treatment of advanced primary Parkinson's disease.
Condition or disease: Parkinson's Disease Intervention/treatment: Drug: KL002 Phase: NA
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yang Ruan, M.D.
- Phone Number: +86 18858736151
- Email: 11818236@zju.edu.cn
Study Contact Backup
- Name: Jiali Pu, Ph.D.
- Email: jialipu@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Second Affiliated Hospital of Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males/females between 40 and 70 years (inclusive)
- Diagnosed with idiopathic Parkinson's disease, Hoehn and Yahr stage 4 and 5
- Disease duration at least 5 years
- MDS UPDRS Part III (total motor) score ≥ 25 and a maximum of 60 in the OFF state
- Good compliance and can complete all follow-up in accordance with the protocol requirements
Exclusion Criteria:
- Prior brain surgery including deep brain stimulation or abnormal brain imaging.
- Presence of depression as measured by Hamilton Depression Scale ≥20
- History of brain injury or central nervous system infection.
- Cognitive impairment score<26 on MoCA and ≤ 20 on MMSE dementia scale
- Evidence of significant medical or psychosis, such as dementia, psychosis, and a history of drug abuse
- Atypical or secondary parkinsonism, including but not limited to symptoms believed to be due to trauma, brain tumor, infection, cerebrovascular disease, other neurological disease, or to drugs, chemicals, or toxins.
- Prior gene therapy.
- Chronic immunosuppressive therapy, including chronic steroids, immunotherapy, cytotoxic therapy and chemotherapy
- Any other conditions that the investigator believed unsuitable for participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: KL002 injection solution
single dose, neurosurgically infused, bilaterally into the striatum
|
Neurosurgical delivery of KL002 to the brain
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Treatment Emergent Adverse Events
Time Frame: Day 0 through month 24
|
Safety and Tolerability of KL002 assessed by Treatment Emergent Adverse Events
|
Day 0 through month 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Parkinson's Symptoms
Time Frame: Day 0 through month 24
|
Effect of KL002 on Parkinson's symptoms as recorded in subject diaries, neurological, motor, and non-motor assessments, quality of life surveys and changes to Parkinson's medications.
|
Day 0 through month 24
|
|
PET Scan Imaging
Time Frame: Day 0 through month 24
|
Relationship between KL002 distribution in the brain and change in dopamine expression as indicated in PET imaging.
|
Day 0 through month 24
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Baorong Zhang, M.D., The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou, Zhejiang province, China, 310009
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-0013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.